6HD2

Active-site conformational dynamics of carbonic anhydrase II under native conditions: An NMR perspective

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	0.5 mM [U-13C; U-15N] hCAII, 0.5 mM [U-13C; U-15N]2H hCAII, 0.6 mM [U-100% 15N] hCAII, 0.6 mM [U-100% 13C] hCAII, 1 mM hCAII	90% H2O/10% D2O	100 mM	7.4	1 atm	298	Bruker AVANCE III 800
2	3D 1H-15N NOESY	0.5 mM [U-13C; U-15N] hCAII, 0.5 mM [U-13C; U-15N]2H hCAII, 0.6 mM [U-100% 15N] hCAII, 0.6 mM [U-100% 13C] hCAII, 1 mM hCAII	90% H2O/10% D2O	100 mM	7.4	1 atm	298	Bruker AVANCE III 800
3	3D 1H-13C NOESY aliphatic	0.5 mM [U-100% 13C; U-100% 15N] hCAII, 0.5 mM [U-99% 13C; U-99% 15N] hCAII, 0.5 mM [U-99% 15N] hCAII, 0.6 mM [U-13C; U-15N; U-2H] hCAII, 0.6 mM [U-10% 13C] hCAII	100% D2O	100 mM	7.4	1 atm	298	Bruker AVANCE III 800
4	3D 1H-13C NOESY aromatic	0.5 mM [U-100% 13C; U-100% 15N] hCAII, 0.5 mM [U-99% 13C; U-99% 15N] hCAII, 0.5 mM [U-99% 15N] hCAII, 0.6 mM [U-13C; U-15N; U-2H] hCAII, 0.6 mM [U-10% 13C] hCAII	100% D2O	100 mM	7.4	1 atm	298	Bruker AVANCE III 800
5	3D HNCA	0.5 mM [U-100% 13C; U-100% 15N] hCAII, 0.5 mM [U-99% 13C; U-99% 15N] hCAII, 0.5 mM [U-99% 15N] hCAII, 0.6 mM [U-13C; U-15N; U-2H] hCAII, 0.6 mM [U-10% 13C] hCAII	100% D2O	100 mM	7.4	1 atm	298	Bruker AVANCE III 800

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE III	800
2	Bruker	AVANCE III	800

NMR Refinement
Method	Details	Software
simulated annealing		CNS

NMR Ensemble Information
Conformer Selection Criteria	structures with the least restraint violations
Conformers Calculated Total Number	500
Conformers Submitted Total Number	20
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	refinement	CNS		Brunger A. T. et.al.
2	structure calculation	ARIA	2.3	Linge, O'Donoghue and Nilges
3	chemical shift assignment	CARA		Keller and Wuthrich
4	processing	TopSpin		Bruker Biospin
5	peak picking	CcpNmr Analysis		CCPN

RCSB PDB Core Operations are funded by the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.